Anika Therapeutics Inc (ANIK)vsHaleon plc (HLN)
ANIK
Anika Therapeutics Inc
$20.86
-0.62%
HEALTHCARE · Cap: $279.17M
HLN
Haleon plc
$9.19
-0.33%
HEALTHCARE · Cap: $44.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 9143% more annual revenue ($11.15B vs $120.65M). HLN leads profitability with a 14.5% profit margin vs -3.1%. ANIK appears more attractively valued with a PEG of 2.20. HLN earns a higher WallStSmart Score of 51/100 (C-).
ANIK
Hold39
out of 100
Grade: F
HLN
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.8%
Fair Value
$32.86
Current Price
$20.86
$12.00 discount
Intrinsic value data unavailable for HLN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Reasonable price relative to book value
15.6% revenue growth
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Areas to Watch
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of -8.3% — below average capital efficiency
Earnings declined 50.5%
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ANIK
The strongest argument for ANIK centers on Altman Z-Score, Debt/Equity, Price/Book. Revenue growth of 15.6% demonstrates continued momentum.
Bull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bear Case : ANIK
The primary concerns for ANIK are PEG Ratio, Market Cap, Return on Equity.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Key Dynamics to Monitor
ANIK profiles as a growth stock while HLN is a value play — different risk/reward profiles.
HLN carries more volatility with a beta of 0.24 — expect wider price swings.
ANIK is growing revenue faster at 15.6% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Bottom Line
HLN scores higher overall (51/100 vs 39/100). ANIK offers better value entry with a 68.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Anika Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.
Visit Website →Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?